Systematic review: comparative effectiveness of adjunctive devices in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention of native vessels by Sobieraj, Diana M et al.
RESEARCH ARTICLE Open Access
Systematic review: comparative effectiveness of
adjunctive devices in patients with ST-segment
elevation myocardial infarction undergoing
percutaneous coronary intervention of native
vessels
Diana M Sobieraj, C Michael White, Jeffrey Kluger, Vanita Tongbram, Jennifer Colby, Wendy T Chen,
Sagar S Makanji, Soyon Lee, Ajibade Ashaye and Craig I Coleman
*
Abstract
Background: During percutaneous coronary intervention (PCI), dislodgement of atherothrombotic material from
coronary lesions can result in distal embolization, and may lead to increased major adverse cardiovascular events
(MACE) and mortality. We sought to systematically review the comparative effectiveness of adjunctive devices to
remove thrombi or protect against distal embolization in patients with ST-segment elevation myocardial infarction
(STEMI) undergoing PCI of native vessels.
Methods: We conducted a systematic literature search of Medline, the Cochrane Database, and Web of Science
(January 1996-March 2011), http://www.clinicaltrials.gov, abstracts from major cardiology meetings, TCTMD, and
CardioSource Plus. Two investigators independently screened citations and extracted data from randomized
controlled trials (RCTs) that compared the use of adjunctive devices plus PCI to PCI alone, evaluated patients with
STEMI, enrolled a population with 95% of target lesion(s) in native vessels, and reported data on at least one pre-
specified outcome. Quality was graded as good, fair or poor and the strength of evidence was rated as high,
moderate, low or insufficient. Disagreement was resolved through consensus.
Results: 37 trials met inclusion criteria. At the maximal duration of follow-up, catheter aspiration devices plus PCI
significantly decreased the risk of MACE by 27% compared to PCI alone. Catheter aspiration devices also
significantly increased the achievement of ST-segment resolution by 49%, myocardial blush grade of 3 (MBG-3) by
39%, and thrombolysis in myocardial infarction (TIMI) 3 flow by 8%, while reducing the risk of distal embolization
by 44%, no reflow by 48% and coronary dissection by 70% versus standard PCI alone. In a majority of trials, the use
of catheter aspiration devices increased procedural time upon qualitative assessment.
Distal filter embolic protection devices significantly increased the risk of target revascularization by 39% although
the use of mechanical thrombectomy or embolic protection devices did not significantly impact other final health
outcomes. Distal balloon or any embolic protection device increased the achievement of MBG-3 by 61% and 20%
and TIMI3 flow by 11% and 6% but did not significantly impact other intermediate outcomes versus control. Upon
qualitative analysis, all device categories, with exception of catheter aspiration devices, appear to significantly
prolong procedure time compared to PCI alone while none appear to significantly impact ejection fraction. Many
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any medium, provided the original work is properly cited.of the final health outcome and adverse event evaluations were underpowered and the safety of devices overall is
unclear due to insufficient amounts of data.
Conclusions: In patients with STEMI, for most devices, few RCTs evaluated final health outcomes over a long
period of follow-up. Due to insufficient data, the safety of these devices is unclear.
Background
Over 650,000 deaths were attributed to coronary heart
disease (CHD) in the United States in 2003 [1]. Coron-
ary stents and adjunctive pharmacologic agents have
improved the effect of percutaneous coronary interven-
tion (PCI), establishing near normal antegrade blood
flow in the vast majority of patients [1-4]. However, dis-
lodgement of atherothrombotic material from coronary
lesions during PCI can result in distal embolization,
termed the “no-reflow phenomenon, in 12 to 39 percent
of patients” [1,2].
Patients with no-reflow may have larger infarcts, more
significant left ventricular systolic dysfunction, and an
increased risk of major adverse cardiovascular events
(MACE) or death. Numerous adjunctive devices have been
developed to remove thrombi or protect against distal
embolization during PCI [5]. These devices utilize different
technologies and can be broadly classified as catheter
aspiration, mechanical thrombectomy, or embolic protec-
tion devices (i.e., distal embolic balloon or filter protection
devices or proximal embolic balloon protection devices)
[6]. Distal embolic protection devices are recommended to
be used in patients undergoing PCI of saphenous vein
grafts due to previously demonstrated ability to reduce
MACE [1,2]. However, use of embolic protection devices
in STEMI has been less well supported mainly because of
underpowered clinical trials that evaluated intermediate
markers [2]. More recently, larger randomized controlled
trials (RCTs) of patients with STEMI have evaluated
MACE as an end point and followed patients beyond hos-
pital discharge (typically 3 to 12 months) but have given
conflicting results [7-17]. The Agency for Healthcare
Research and Quality commissioned this report to system-
atically review the comparative effectiveness of adjunctive
devices to remove thrombi or protect against distal embo-
lization in patients with acute coronary syndromes (ACS)
undergoing PCI of native vessels.
Methods
We developed and followed a standard protocol for all
steps of this review, which underwent review by a panel
of experts in the field as well as the public. The peer-
reviewed final report details the methodology including
the analytic framework, literature search strategy, and
analysis plan as well as evidence tables and is available
at http://www.effectivehealthcare.ahrq.gov. The authors
have no conflicts of interest.
We refined key questions in collaboration with a panel
of technical experts which included cardiologists, inter-
nists, and representatives from managed-care organiza-
tions. The following key questions in patients with
STEMI who are undergoing PCI of native vessels were
defined:
1. What are the comparative effects of adjunctive
devices from different classes on intermediate [e.g.
ST-segment resolution (STSR), myocardial blush
grade (MBG), thrombolysis in myocardial infarction
(TIMI) 3 flow, ejection fraction, no reflow and distal
embolization)] and final health outcomes [mortality,
MACE, and health-related quality-of-life (HRQoL)]?
2. How do the rate and type of harms (e.g. coronary
dissection, coronary perforation, and prolonged pro-
cedure time) differ between device types when com-
pared to PCI alone?
The final report of this comparative effectiveness
review, available at http://www.effectivehealthcare.ahrq.
gov, includes information and results of analyses specific
to patients with non-ST-segment myocardial infarction
(NSTEMI), unstable angina (UA), or mixed ACS
(STEMI, NSTEMI, and/or UA), results from observa-
tional trials with over 500 patients, and information on
results in various subpopulations.
Data Sources
We conducted a computerized literature search of Med-
line, Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews, and Web of
Science databases from January 1996- March 2010, with-
out language restrictions. We restricted the search to
1996 and later to reflect contemporary practice. The
complete search strategy is included in Additional File 1.
Additionally, in an attempt to locate unpublished studies
and increase the sensitivity of our search, we reviewed
references from identified studies and systematic reviews.
We searched for and reviewed abstracts from major car-
diology meetings (American Heart Association, Ameri-
can College of Cardiology, European Society of
Cardiology), Transcatheter Cardiovascular Therapeutics
(TCT) Conference of the Cardiovascular Research Foun-
dation and the TCTMD http://www.tctmd.com, Cardio-
Source Plus http://www.cardiosource.com, and http://
ClinicalTrials.govhttp://www.clinicaltrials.gov web sites.
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the peer review period using the same search strategy.
Study Selection
Two independent reviewers assessed studies for inclu-
sion in a parallel manner using a priori criteria. RCTs of
any size were eligible for inclusion if they: 1) compared
the use of adjunctive devices plus PCI to PCI alone, 2)
included patients with STEMI, 3) had ≤ 5% of the study
population receiving PCI of saphenous veins, and (4)
reported data on at least one pre-specified intermediate
outcome, final health outcome, or harm. Given the
known benefit of distal embolic protection devices in
patients undergoing PCI of a saphenous vein graft, this
review was restricted to a population with lesions pri-
marily in native vessels.
Data Extraction
Two reviewers used a standardized data extraction tool
to independently extract study data. Data extracted from
each study included interventions, study design, inclu-
sion and exclusion criteria, methodological quality cri-
teria, study population, baseline patient characteristics,
use of concurrent standard medical therapies, and pre-
specified benefits and harms.
Assessment of Study Quality and Strength of Evidence
Two reviewers independently assessed the validity and
strength of evidence using recommendations in the
Methods Guide for Effectiveness and Comparative Effec-
tiveness Reviews [18]. We assessed each study for the
following individual criteria: randomization technique,
comparable study groups at baseline, detailed descrip-
tion of study outcomes, blinding of outcome assessors,
intent-to-treat analysis, description of participant with-
drawals (percent follow-up), and potential conflict of
interest. Studies were then given an overall quality score
of good, fair, or poor.
We used a modified version of the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system to assess the strength of evidence for
each outcome of interest. Four required domains were
evaluated- risk of bias, consistency, directness, and pre-
cision. We classified the strength of evidence for each
outcome as high, moderate, low, or insufficient.
Data Synthesis and Analysis
We qualitatively examined data from all identified stu-
dies. Six device classes were considered and for each
outcome, we conducted separate analyses of studies that
compare each device class with control or two device
classes to each other. Device classes included catheter
aspiration, mechanical thrombectomy, distal filter
embolic protection, distal balloon embolic protection,
proximal balloon embolic protection, and embolic pro-
tection devices combined (distal or proximal, balloon or
filter). We conducted meta-analyses when two or more
RCTs that were adequate for data pooling were available
for any outcome. For dichotomous outcomes, weighted
averages are reported as relative risks (RR) and risk dif-
ferences (RD) with associated 95 percent confidence
intervals using a DerSimonian and Laird random-effects
model [19]. We used automatic ‘zero cell’ correction for
studies with no events for a particular outcome occur-
ring in one group. We excluded studies with no events
occurring in the treatment and control groups. We
addressed statistical heterogeneity using the I
2 statistic
(with a value > 50% deemed to be representative of sig-
nificant heterogeneity) and we used Egger’sw e i g h t e d
regression statistic to assess for the presence of publica-
tion bias [20]. We used StatsDirect statistical software,
version 2.7.8 (StatsDirect Ltd., Cheshire, England) with a
p-value of < 0.05 considered statistically significant.
We defined attainment of optimal myocardial reperfu-
sion as a MBG-3 or TIMI-3 blood flow (or a MBG or
TIMI blood flow of at least two in studies not reporting
the other endpoint) and ST-segment resolution as 70
percent resolution in peak ST-segments (or at least 50
percent resolution in studies not reporting the other
endpoint). We used results for ST-segment resolution at
or close to 60 minutes post-PCI and never exceeding 90
minutes post-PCI. For final health outcomes, we defined
the base-case analysis using the maximum duration of
follow-up for which a final health outcome was
reported.
To assess the effect of heterogeneity (both clinical and
methodological) on the conclusions of our meta-analy-
sis, we conducted subgroup and sensitivity analyses
based on study quality (limited to good quality trials)
and duration of follow-up on the efficacy of adjunctive
devices. Data at different follow-up times (in-hospital, ≥
30 days but < 180 days, ≥ 180 days but < 365 days, and
≥ 365 days) were pooled in separate subgroup analyses.
Role of the Funding Source
The University of Connecticut/Hartford Hospital Evi-
dence-based Practice Center prepared this systematic
review, with funding from the Agency of Healthcare
Research and Quality. The funding source formulated
draft research questions and provided the copyright
release for this manuscript, but did not participate in
the literature search, data collection or analysis, or inter-
pretation of the results.
Results
We screened 1,091 abstracts and 438 full text articles
(Figure 1). Specific to the STEMI population, we
included 37 unique RCTs [7-17,21-47].
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Diagram Abbreviations: n = number; PCI = percutaneous
coronary intervention; PRISMA = preferred reporting items for systematic reviews and meta-analyses; RCT = randomized controlled trial; STEMI =
ST segment elevation myocardial infarction.
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with STEMI
All RCTs compared an adjunctive device plus PCI to
standard PCI alone. Compared to standard PCI, 17 trials
evaluated catheter aspiration devices [8-12,15-17,21-30]
(n = 3355; 11 good, 3 fair and 3 poor quality trials), 5
trials evaluated mechanical thrombectomy devices
[7,31-34] (n = 1374; 5 good quality), 9 trials evaluated
distal balloon embolic protection devices [13,35-42] (n =
1479; 8 good and 1 fair quality), 5 trials evaluated distal
filter embolic protection devices [43-47] (n = 962; 4 good
and 1 fair quality), and trial evaluated proximal balloon
embolic protection devices [14] (n = 284, good quality).
The baseline characteristics of included trials are pre-
sented in Additional File 2, Table S1. The mean age of
patients enrolled in the 37 trials ranged from 55 to 69
years presenting within 6 to 48 hours of symptom onset.
Twenty-one of the 34 trials included patients presenting
within 12 hours of symptom onset. Males constituted at
least half of the patients in the trials, ranging from 55 to
95 percent of the total population. The mean ischemic
time reported in the 37 trials ranged from 120 to 510
minutes. The percent of patients presenting with TIMI
0/1 at baseline ranged from 55 to 100 percent. Of the
37 trials, 24 trials included patients with no prior fibri-
nolysis before the index PCI. Five trials included
patients with prior fibrinol y s i sa sw e l la sp r i m a r yP C I
and eight trials did not report whether patients who
received prior fibrinolysis were included.
Final Health Outcomes
Maximum Duration of Follow-Up Analyses
The use of catheter aspiration devices plus PCI signifi-
cantly decreased the risk of MACE compared to PCI
alone by 27% and showed trends (upper or lower extent
of the 95% confidence intervals within 0.05 units of the
line of unity) towards reducing mortality, myocardial
infarction, and target revascularization versus PCI alone
(Table 1). Distal filter embolic protection devices signifi-
cantly increased the risk of target revascularization by
61% compared to PCI alone. Mechanical thrombectomy,
distal balloon embolic protection, proximal balloon
embolic protection, and the combined group of embolic
protection devices plus PCI failed to significantly impact
any final health outcome versus PCI alone (Additional
file 3 to 25). All of the adjunctive devices non-signifi-
cantly increased the risk of stroke versus PCI alone.
Limiting studies to those of good methodological quality
did not alter any of these results. No trials evaluated the
impact of adjunctive devices on HRQoL.
Time Specified Analyses
When we evaluated final health outcomes over several
different time periods, we found several significant find-
ings (Table 2). Catheter aspiration devices plus PCI
significantly reduced the risk of mortality at 365 days
while target revascularization and MACE were signifi-
cantly reduced at 180 days versus PCI alone. Mechanical
aspiration devices plus PCI reduced target revasculariza-
tion at 180 days and MACE at 365 days versus PCI
alone. Distal filter embolic protection devices plus PCI
paradoxically significantly increased the risk of target
revascularization and MACE at 365 days versus PCI
alone. Based on a single RCT, distal balloon embolic
protection devices plus PCI significantly reduced the
risk of in hospital and 90 day stroke versus PCI alone.
Intermediate Health Outcomes
The use of catheter aspiration devices plus PCI signifi-
cantly increased the achievement of STSR by 51%,
MBG-3 by 61% and TIMI-3 flow by 8% while they sig-
nificantly decreased the risk of no reflow by 52% and
distal embolization by 56% versus PCI alone (Table 3
and Additional file 26 to 49). The use of either distal
balloon embolic protection device or the combined
group of embolic protection devices plus PCI signifi-
cantly increased achievement of MBG-3 (39% and 20%,
respectively) and TIMI-3 flow (11% and 6%, respec-
tively) versus PCI alone. Embolic protection devices
showed a trend towards improvement in attaining
STSR, however, neither device category significantly
impacted STSR, distal embolization, and no reflow ver-
sus PCI alone. Mechanical thrombectomy devices, distal
filter embolic protection and proximal balloon embolic
protection devices failed to significantly impact STSR,
MBG-3, TIMI-3, no reflow and distal embolization,
although no trials evaluated proximal embolic balloon
protection devices on the risk of no reflow versus PCI
alone. All three device categories demonstrated trends
toward improvement in attaining STSR and MBG while
proximal balloon embolic protection devices showed
trends toward improvement in MBG-3 versus PCI
alone. However, the proximal balloon embolic protec-
tion device data were based on a single trial. Limiting
studies to those of good methodological quality did not
alter any of these results.
We qualitatively evaluated ejection fraction for each
device category versus standard PCI (Table 4). Based on
the majority of trials within each device category, none
o ft h ea d j u n c t i v ed e v i c e sc a tegories appear to signifi-
cantly impact ejection fraction versus standard PCI.
However, data were inconsistently reported across trials
and the time period in which ejection fraction was mea-
sured varied from in-hospital to 6 months post-PCI,
preventing rational pooling of results.
Harms
The use of catheter aspiration devices plus PCI signifi-
cantly decreased the risk of coronary dissection by 70%
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Page 5 of 19Table 1 Effect of adjunctive devices on final health outcomes
Outcome N trials/N
pooled
WMF
(M)
RR
(95% CI)
I
2 SOE* N trials/N
pooled
WMF
(M)
RR
(95% CI)
I
2
All eligible trials Limited to good quality trials
Catheter Aspiration
Mortality 11/10 7.92 0.69 (0.47 to 1.02) 0% Low 10/10 8.08 0.70 (0.47 to 1.03) 0%
Myocardial
infarction
10/10 8.80 0.61 (0.36 to 1.04) 0% Low 10/10 8.80 0.61 (0.36 to 1.04) 0%
Stroke 5/4 0.79 3.18 (0.73 to 13.88) 0% Insufficient 5/4 0.79 3.18 (0.73 to 13.88) 0%
Target
revascularization
9/9 9.48 0.79 (0.61 to 1.02) 0% Low 9/9 9.48 0.79 (0.61 to 1.02) 0%
MACE 11/11 12.43 0.73 (0.61 to 0.88) 0% High 11/11 12.43 0.73 (0.61 to 0.88) 0%
HRQoL 0 —— — Insufficient 0 —— —
Mechanical
Thrombectomy
Mortality 5/4 7.80 1.19 (0.51 to 2.76) 54.9 Insufficient 5/4 7.80 1.19 (0.51 to 2.76) 54.9
Myocardial
infarction
5/3 8.98 0.71 (0.27 to 1.85) 0% Insufficient 5/3 8.98 0.71 (0.27 to 1.85) 0%
Stroke 5/4 5.79 2.42 (0.75 to 7.78) 0% Insufficient 5/4 5.79 2.42 (0.75 to 7.78) 0%
Target
revascularization
5/3 6.22 0.87 (0.36 to 2.10) 39.2% Insufficient 5/3 6.22 0.87 (0.36 to 2.10) 39.2%
MACE 4/3 6.22 1.23 (0.50 to 3.01) 79.9% Insufficient 4/3 6.22 1.23 (0.50 to 3.01) 79.9%
HRQoL 0 —— — Insufficient 0 —— —
Distal Filter Embolic
Protection
Mortality 5/5 10.84 0.97 (0.54 to 1.75) 0% Insufficient 4/4 11.49 0.97 (0.53 to 1.79) 0%
Myocardial
infarction
5/4 11.22 0.72 (0.15 to 3.34) 39.8% Insufficient 4/3 11.93 0.56 (0.06 to 5.02) 60%
Stroke 1/0 1 1.51 (0.30 to 7.52)
† NA Insufficient 1/0 1 1.51 (0.30 to 7.52)
† NA
Target
revascularization
3/2 13.36 1.61 (1.03 to 2.54) NA Low 3/2 13.36 1.61 (1.03 to 2.54) NA
MACE 5/5 10.84 1.34 (0.97 to 1.86) 0% Moderate 4/4 11.49 1.36 (0.98 to 1.89) 0%
HRQoL 0 —— — Insufficient 0 —— —
Distal Balloon Embolic Protection
Mortality 4/4 6 0.82 (0.45 to 1.51) 2.5% Insufficient 4/4 6 0.82 (0.45 to 1.51) 2.5%
Myocardial
infarction
5/5 6 0.67 (0.29 to 1.57) 0% Insufficient 5/5 6 0.67 (0.29 to 1.57) 0%
Stroke 1 6 0.48 (0.10 to 2.22)
† NA Insufficient 1/0 6 0.48 (0.10 to 2.22)
† NA
Target
revascularization
5/5 6 0.93 (0.61 to 1.42) 0% Insufficient 5/5 6 0.93 (0.61 to 1.42) 0%
MACE 6/5 6 0.87 (0.64 to 1.19) 0% Insufficient 6/5 6 0.87 (0.64 to 1.19) 0%
HRQoL 0 —— — Insufficient 0 —— —
Proximal Balloon Embolic Protection
Mortality 1/0 6 0.51 (0.11 to 2.33)
† NA Insufficient 1/0 6 0.51 (0.11 to 2.33)
† NA
Myocardial
infarction
1/0 6 1.01 (0.24 to 4.33)
† NA Insufficient 1/0 6 1.01 (0.24 to 4.33)
† NA
Stroke 1/0 6 0.20 (0 to 1.93)
† NA Insufficient 1/0 6 0.20 (0 to 1.93)
† NA
Target
revascularization
1/0 6 0.71 (0.29 to 1.75)
† NA Insufficient 1/0 6 0.71 (0.29 to 1.75)
† NA
MACE 1/0 6 0.74 (0.36 to 1.54)
† NA Insufficient 1/0 6 0.74 (0.36 to 1.54)
† NA
HRQoL 0 —— — Insufficient 0 —— —
Embolic Protection
Devices
Mortality 10/10 8.11 0.87 (0.58 to 1.30) 0% Insufficient 9/9 8.31 0.87 (0.57 to 1.31) 0%
Myocardial
infarction
11/10 8.08 0.83 (0.45 to 1.53) 0% Insufficient 10/9 8.27 0.83 (0.45 to 1.55) 0%
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one trial evaluating coronary perforation (Table 3 and
Additional file 50 to 54). Mechanical thrombectomy,
distal filter embolic protection, distal balloon embolic
protection, and the combined group of embolic protec-
tion devices plus PCI failed to significantly impact or
show trends towards impacting these harms versus PCI
alone. However, analyses were generally limited to a
small number of trials and in some cases no events
occurred so the risk of harms could not be calculated.
Limiting studies to those of good methodological quality
did not alter any of these results. No trials evaluated
these harms for proximal balloon embolic protection
devices.
Catheter aspiration devices plus PCI does not appear
to prolong procedure time since a majority of trials (8
of 9 trials) evaluating this outcome found no significant
differences versus PCI alone (Table 4). Mechanical
thrombectomy (3 of 3 trials), distal balloon embolic pro-
tection (2 of 3 trials), distal filter embolic protection (1
of 1 trial) proximal balloon embolic protection devices
(1 of 1 trial) and embolic protection devices (4 of 5
trials) plus PCI appear to prolong procedure time versus
standard PCI.
Discussion
Determining the balance of benefits to harms is difficult
because many of the final health outcome and adverse
event evaluations were underpowered and the safety of
devices overall is unclear due to insufficient amounts of
data. We do not know for certain whether the non-sig-
nificant increases or decreases observed were due to a
real effect or to chance.
In the catheter aspiration trials, the risk of MACE and
coronary dissection were significantly lower in the over-
all analyses and the good quality trial analyses. However,
the risk of mortality, myocardial infarction, and target
revascularization were not significantly impacted
(although there was a trend in the right direction) and a
non-significant increase in the risk of stroke was found.
However, STSR, MBG-3, TIMI-3, no reflow, and distal
embolization were favorably impacted by catheter
aspiration devices compared to standard PCI. As such,
more research is needed to truly determine the balance
of benefits to harms but use of catheter aspiration
devices looks promising.
Mechanical thrombectomy device use did not result in
any significant differences in the final health outcomes
or coronary dissection and coronary perforation in the
overall analyses and analyses limited to good quality
trials. However, these devices significantly increased the
time needed to conduct the PCI procedure in three
trials. While the risk of myocardial infarction, target
revascularization, mortality and MACE were not signifi-
cantly different versus control, these findings may be
misleading since many of the trials evaluating this pro-
cedure versus control had a shorter duration of follow-
up. When we evaluated mortality and MACE in studies
of 365 days or longer, there was no significant difference
in mortality risk although there was a significant reduc-
tion in MACE, based on the results of a single trial.
Unlike with catheter aspiration devices, there are no sig-
nificant beneficial effects on intermediate health out-
comes and while most are in the right direction of
effect, the chance of achieving near normal (TIMI-3)
blood flow was not significantly different versus control.
As such, more research is needed to truly determine the
balance of benefits to harms with mechanical throm-
bectomy devices.
The use of embolic protection devices was based on a
limited number of studies and one significant finding
(the positive impact of distal filter devices on target
revascularization) on final health outcomes was seen in
overall analyses and those limited to good quality trials.
It was difficult to assess the impact on final health out-
comes and intermediate outcomes for these devices.
Distal balloon devices significantly increased the chance
of achieving a MBG-3 or near normal (TIMI-3) blood
flow but did not significantly impact the achievement of
STSR, prevention of no reflow, or the risk of distal
embolization. Distal filter devices did not significantly
impact STSR, distal embolization, no reflow, attainment
of near normal (TIMI-3) blood flow, or MBG. There
was a paucity of trials available to evaluate adverse
Table 1 Effect of adjunctive devices on final health outcomes (Continued)
Stroke 3/3 3.74 0.68 (0.22 to 2.11) 0% Insufficient 3/3 3.74 0.68 (0.22 to 2.11) 0%
Target
revascularization
9/8 8.60 1.11 (0.80 to 1.52) 10% Insufficient 9/8 8.60 1.11 (0.80 to 1.52) 10%
MACE 12/11 7.97 1.04 (0.84 to 1.29) 0% Moderate 11/10 8.15 1.03 (0.82 to 1.29) 4%
HRQoL 0 —— — Insufficient 0 —— —
Abbreviations: CI = confidence interval; HRQoL = health-related quality of life; m = months; MACE = major adverse cardiovascular events; N = number; NA = not
applicable; RR = relative risk; SOE = strength of evidence; WMF = weighted mean follow-up
* Strength of evidence is rated for the primary base analyses only. Subgroup analyses were not rated with strength of evidence; include limiting the analysis to
trials of good methodological quality.
†Result is based on a single trial
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Outcome WMF (M) ≤ 30d RR
(95% CI)
In-hospital RR (95% CI) 30d RR
(95% CI)
180d RR
(05% CI)
365d RR
(95% CI)
Catheter Aspiration
Mortality 0.79 0.65 (0.39 to 1.10) 0.81 (0.23 to 2.86) 0.61 (0.35 to 1.07) 0.89 (0.31 to 2.51) 0.62 (0.39 to 0.98)
Myocardial infarction 0.77 0.55 (0.24 to 1.25) 0.32 (0.03 to 3.06) 0.60 (0.25 to 1.45) 0.70 (0.24 to 1.99) 0.51 (0.26 to 1.00)
Stroke 0.79 3.18 (0.73 to 13.88) 4.94 (0.52 to infinity) 2.77 (0.51 to 14.98) —* —†
Target
revascularization
0.70 0.85 (0.53 to 1.38) 1.35 (0.26 to 6.94) 0.82 (0.50 to 1.35) 0.62 (0.40 to 0.96) 0.87 (0.63 to 1.19)
MACE 0.79 0.80 (0.57 to 1.12) 0.97 (0.36 to 2.58) 0.79 (0.56 to 1.13) 0.66 (0.47 to 0.94) 0.61 (0.26 to 1.41)
HRQoL —— — — — —
Mechanical Thrombectomy
Mortality 1 1.25 (0.47 to 3.32) 1.00 (0.24 to 4.16)‡ 1.25 (0.47 to 3.32) 1.35 (0.53 to 3.44) 0.50 (0.21 to 1.17)
Myocardial infarction 1 0.63 (0.21 to 1.96) 1.00 (0.11 to 9.41)‡ 0.63 (0.21 to 1.96) 0.57 (0.17 to 1.92) 0.66 (0.13 to 3.29)
Stroke 1 1.89 (0.55 to 6.48) —* 1.89 (0.55 to 6.48) 2.05 (0.27 to 15.78) 1.99 (0.26 to 15.14)
Target
revascularization
1 1.62 (0.21 to 12.55) —* 1.62 (0.21 to 12.55) 0.55 (0.33 to 0.92) 0.68 (0.41 to 1.13)
MACE 1 1.28 (0.37 to 4.38) —† 1.28 (0.37 to 4.38) 0.71 (0.41 to 1.20) 0.66 (0.44 to 0.97)
HRQoL —— — — — —
Distal Filter Embolic Protection
Mortality 1 1.02 (0.50 to 2.08) —† 1.02 (0.50 to 2.08) 1.25 (0.38 to 4.16)‡ 0.87 (0.43 to 1.78)‡
Myocardial infarction 1 0.73 (0.12 to 4.44) —† 0.73 (0.12 to 4.44) 0.09 (0 to 0.74)* 2.35 (0.61 to 8.90)‡
Stroke 1 1.51 (0.30 to 7.52)‡— † 1.51 (0.30 to 7.52)‡— † — †
Target
revascularization
1 3.02 (0.61 to 14.84) —† 3.02 (0.70 to 13.01)‡ 1.00 (0.35 to 2.82)‡ 1.78 (1.09 to 2.93)‡
MACE 1 1.29 (0.77 to 2.15) —† 1.29 (0.77 to 2.15) 1.10 (0.68 to 1.78) 1.48 (1.03 to 2.15)‡
HRQoL —— — — — —
Distal Balloon Embolic Protection
Mortality 1 0.64 (0.30 to 1.39) 0.69 (0.24 to 2.03)‡ 0.64 (0.30 to 1.39) 0.86 (0.48 to 1.57) —†
Myocardial infarction 1 0.85 (0.32 to 2.23) 0.32 (0.00 to 3.71)‡ 0.85 (0.32 to 2.23) 0.67 (0.29 to 1.57) —†
Stroke 1 0.11 (0 to 0.94)‡— † 0.11 (0 to 0.94)‡ 0.48 (0.10 to 2.22)‡— †
Target
revascularization
1 1.38 (0.55 to 3.50) 0.32 (0.00 to 3.71)‡ 1.38 (0.55 to 3.50) 0.93 (0.61 to 1.42) —†
MACE 1 0.74 (0.44 to 1.23) —* 0.74 (0.44 to 1.23) 0.87 (0.64 to 1.19) —†
HRQoL —— — — — —
Proximal Balloon Embolic Protection
Mortality 1 1.01 (0.14 to 7.10)‡— † 1.01 (0.18 to 5.69)‡ 0.51 (0.11 to 2.33)‡— †
Myocardial infarction 1 0.68 (0.11 to 3.99)‡— † 0.68 (0.14 to 3.34)‡ 1.01 (0.24 to 4.33)‡— †
Stroke 1 0.34 (0.01 to 8.23)‡— † 0.34 (0 to 3.87)‡ 0.20 (0.00 to 1.93)‡— †
Target
revascularization
1 0.51 (0.13 to 1.99)‡— † 0.51 (0.14 to 1.81)‡ 0.71 (0.29 to 1.75)‡— †
MACE 1 0.61 (0.23 to 1.63)‡— † 0.61 (0.23 to 1.57)‡ 0.74 (0.36 to 1.54)‡— †
HRQoL —— — — — —
Embolic Protection Devices
Mortality 1 0.84 (0.50 to 1.39) 0.69 (0.24 to 2.03)‡ 0.84 (0.50 to 1.39) 0.87 (0.52 to 1.46) 0.87 (0.43 to 1.78)‡
Myocardial infarction 1 0.83 (0.41 to 1.69) 0.32 (0.00 to 3.71)‡ 0.83 (0.41 to 1.69) 0.65 (0.31 to 1.33) 2.35 (0.61 to 8.90)‡
Stroke 1 0.56 (0.11 to 2.84) —† 0.56 (0.11 to 2.84) 0.39 (0.09 to 1.71) —†
Target
revascularization
1 1.24 (0.62 to 2.48) 0.32 (0.00 to 3.71)‡ 1.24 (0.62 to 2.48) 0.90 (0.63 to 1.30) 1.78 (1.09 to 2.93)‡
MACE 1 0.92 (0.66 to 1.30) —* 0.92 (0.66 to 1.30) 0.91 (0.71 to 1.16) 1.48 (1.03 to 2.15)‡
HRQoL —— — — — —
Abbreviations: d = day; CI = confidence interval; HRQoL = health-related quality of life; m = months; MACE = major adverse cardiovascular events; N = number; =
relative risk; WMF = weighted mean follow-up
* Risk could not be calculated because no events occurred in the trial evaluating this outcome
† Risk could not be calculated because no trials evaluated this outcome
‡ Result is based on a single trial
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Page 8 of 19Table 3 Effect of adjunctive devices on intermediate health outcomes and harms
Outcome N trials/N
pooled
Relative Risk
(95% CI)
I
2 Strength of
Evidence*
N trials/
N
pooled
Relative Risk
(95% CI)
I
2
Intermediate Outcomes
All eligible trials Limited to good quality trials
Catheter Aspiration
ST-segment resolution 15/15 1.51 (1.32 to 1.73) 64.2% Moderate 10/10 1.39 (1.21 to 1.61) 60.4%
MBG-3 13/13 1.61 (1.41 to 1.84) 55.4% Moderate 9/9 1.75 (1.44 to 2.14) 69.2%
TIMI-3 13/13 1.08 (1.04 to 1.12) 11.5% Moderate 10/10 1.07 (1.04 to 1.11) 0%
Distal embolization 10/10 0.56 (0.39 to 0.79) 43.4% High 8/8 0.48 (0.34 to 0.66) 33.7%
No reflow 8/8 0.52 (0.35 to 0.76) 15.7% High 6/6 0.45 (0.27 to 0.75) 22.3%
Mechanical Thrombectomy
ST-segment resolution 5/5 1.16 (0.99 to 1.36) 75.1% Low 5/5 1.16 (0.99 to 1.36) 75.1%
MBG-3 4/4 1.07 (0.80 to 1.43) 76.5% Low 4/4 1.07 (0.80 to 1.43) 76.5%
TIMI-3 4/4 0.98 (0.92 to 1.04) 67.5% Moderate 4/4 0.98 (0.92 to 1.04) 67.5%
Distal embolization 3/3 0.44 (0.17 to 1.12) 41.6% Moderate 3/3 0.44 (0.17 to 1.12) 41.6%
No reflow 3/3 0.50 (0.17 to 1.48) 41.7% Insufficient 3/3 0.50 (0.17 to 1.48) 41.7%
Distal Filter Embolic Protection
ST-segment resolution 5/5 1.05 (0.97 to 1.15) 0% Moderate 4/4 1.05 (0.96 to 1.14) 0%
MBG-3 2/2 0.97 (0.81 to 1.15) NA Moderate 2/2 0.97 (0.81 to 1.15) NA
TIMI-3 5/5 1.00 (0.90 to 1.11) 69.6% Low 4/4 1.02 (0.90 to 1.15) 70.2%
Distal embolization 1/0 0.63 (0.22 to 1.82)† NA Insufficient 1/0 0.63 (0.22 to 1.82)† NA
No reflow 2/2 0.59 (0.14 to 2.51) NA Insufficient 1/0 1.00 (0.18 to 5.55)† NA
Distal Balloon Embolic Protection
ST-segment resolution 4/4 1.08 (0.91 to 1.29) 41.2% Moderate 4/4 1.08 (0.91 to 1.29) 41.2%
MBG-3 6/6 1.39 (1.15 to 1.69) 43.5% High 6/6 1.39 (1.15 to 1.69) 43.5%
TIMI-3 9/8 1.11 (1.03 to 1.19) 60.4% Low 8/7 1.09 (1.01 to 1.17) 59.7%
Distal embolization 4/4 1.10 (0.67 to 1.81) 5.8% Moderate 4/4 1.10 (0.67 to 1.81) 5.8%
No reflow 4/4 0.51 (0.19 to 1.33) 0% Insufficient 4/4 0.51 (0.19 to 1.33) 0%
Proximal Balloon Embolic
Protection
ST-segment resolution 1/0 1.11 (0.97 to 1.28)† NA Insufficient 1/0 1.11 (0.97 to 1.28)† NA
MBG-3 1/0 0.98 (0.88 to 1.10)† NA Insufficient 1/0 0.98 (0.88 to 1.10)† NA
TIMI-3 1/0 1.06 (0.98 to 1.15)† NA Insufficient 1/0 1.06 (0.98 to 1.16)† NA
Distal embolization 1/0 0.71 (0.37 to 1.35)† NA Insufficient 1/0 0.71 (0.38 to 1.33)† NA
No reflow 1/0 —‡ —‡ Insufficient 1/0 —‡ —‡
Embolic Protection Devices
ST-segment resolution 10/10 1.06 (1.00 to 1.13) 0% Low 10/10 1.06 (1.00 to 1.13) 0%
MBG-3 9/9 1.20 (1.02 to 1.40) 68.2% Moderate 9/9 1.20 (1.02 to 1.40) 68.2%
TIMI-3 15/14 1.06 (1.01 to 1.12) 58.3% Low 15/14 1.06 (1.01 to 1.12) 55.4%
Distal embolization 6/6 0.91 (0.64 to 1.30) 0.2% Moderate 6/6 0.91 (0.64 to 1.30) 0.2%
No reflow 6/6 0.53 (0.24 to 1.18) 0% Insufficient 5/5 0.58 (0.25 to 1.37) 0%
Harms
Catheter Aspiration
Coronary dissection 5/5 0.30 (0.12 to 0.75) 0% High 5/5 0.30 (0.12 to 0.75) 0%
Coronary perforation 1/0 —‡ —‡ Insufficient 1/0 —‡ —‡
Mechanical Thrombectomy
Coronary dissection 1/0 1.51 (0.57 to 4.01)† NA Insufficient 1/0 1.51 (0.57 to 4.01)† NA
Coronary perforation 2/2 1.04 (0.15 to 7.04) NA Insufficient 2/2 1.04 (0.15 to 7.04) NA
Distal Filter Embolic Protection
Coronary dissection 1/0 —‡ —‡ Insufficient 1/0 —‡ —‡
Coronary perforation 1/0 —‡ —‡ Insufficient 1/0 —‡ —‡
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Page 9 of 19events with any of the embolic protection devices. The
only significant finding was an increased time to per-
form a PCI procedure for all three types of embolic pro-
tection devices individually and when evaluated together
versus control. As such, the balance of benefits to harms
cannot be determined for these device classes.
The use of thrombus removal and embolic protection
devices hold promise in the adjunctive treatment of
patients with STEMI undergoing primary PCI. However,
to truly discern the role of these devices in contempor-
ary practice, a number of important research questions
need to be answered. In our analysis, we found that for
many endpoints, non-significant increases or decreases
were seen versus control, even when we evaluated com-
pound endpoints, used the maximum duration of fol-
low-up, and combined three different types of embolic
protection devices together. All of these were strategies
to enhance power to detect differences between groups
but by and large, did not provide adequate power. Ulti-
mately, the impact of using these devices on long-term
final health outcomes versus control needs to be
determined.
Previous systematic reviews have attempted to address
this topic. However, only four of 11 which were identi-
fied through our systematic literature search compre-
hensively included devices from all three device
categories including catheter aspiration devices, mechan-
ical thrombectomy, and embolic protection [48-51].
Albeit comprehensive in the devices evaluated, only the
meta-analysis by Bavry and colleagues, published in
2008, attempted to evaluatead u r a t i o no ff o l l o w - u p
beyond 30 days for final health outcomes, including
stroke, MACE, and its components [50]. However, this
analysis did not include safety outcomes and since then,
additional RCTs have been published, which are
included in our analyses.
Based on these research gaps we propose the following
avenues for future research. We believe that additional
multicenter, randomized, placebo-controlled trials should
be conducted to determine the impact of adjunctive clot
removal or embolic protection devices on final health out-
comes using a long term follow-up versus PCI alone. At
least two such trials are currently ongoing, Thrombus
Aspiration in STEMI in Scandinavia (TASTE) and a Trial
of Routine Aspiration Thrombectomy with PCI versus
PCI alone in Patients with STEMI Undergoing Primary
PCI (TOTAL) [52,53]. Both trials plan to have a longer
duration of follow-up, with the TASTE trial following
patients for 10 years and TOTAL up to 1 year. To truly
determine comparative effectiveness, the devices found to
have the best balance of benefits to harms compared with
standard PCI should be directly compared in a multicen-
ter, randomized, active controlled trial to determine the
impact of adjunctive clot removal or embolic protection
devices on final health outcomes using a long term follow-
up. Such trials should have international representation of
interventional cardiologists and include both tertiary aca-
demic medical centers and large community based hospi-
tals. Conducting these additional clinical trials would
facilitate the conduction of mixed treatment meta-analyses
or individual patient data meta-analyses to estimate the
comparative effectiveness of different device classes.
Conclusion
In patients with STEMI, for most devices, few RCTs
evaluated final health outcomes over a long period of
follow-up. Due to insufficient data, the safety of these
devices is unclear.
Table 3 Effect of adjunctive devices on intermediate health outcomes and harms (Continued)
Distal Balloon Embolic Protection
Coronary dissection 1/0 —‡ —‡ Insufficient 1/0 —‡ —‡
Coronary perforation 1/0 5.11 (0.53 to
infinity)†
NA Insufficient 1/0 5.11 (0.53 to infinity)
†
NA
Proximal Balloon Embolic
Protection
Coronary dissection 0/0 —— Insufficient 0/0 ——
Coronary perforation 0/0 —— Insufficient 0/0 ——
Embolic Protection Devices
Coronary dissection 2/0 —‡ —‡ Insufficient 2/0 —‡ —‡
Coronary perforation 1/0 5.11 (0.53 to
infinity)†
NA Insufficient 1/0 5.11 (0.53 to infinity)
†
NA
Abbreviations: MBG = myocardial blush grade; N = number; NA = not applicable; TIMI = thrombolysis in myocardial infarction
* Strength of evidence is rated for the primary base analyses only. Subgroup analyses were not rated with strength of evidence; include limiting the analysis to
trials of good methodological quality.
† Result is based on a single trial
‡ Risk could not be calculated because no events occurred
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Page 10 of 19Table 4 Ejection fraction and procedure time*
Study, Year Group n Time EF Measured Mean EF (SD) P-value n Mean Procedure Time P-value
Ejection Fraction Procedure Time
Catheter Aspiration
Dudek,
2010
Diver CE
Control
—
—
——
—
——
—
—
—
—
Liistro,
2009
Export Thrombectomy Catheter
Control
55
56
180d 55 (6)
49 (8)
< 0.0001 55
56
75.7 (30.0)
75.9 (38.7)
0.90
Lipiecki,
2009
Export Catheter
Control
20
24
7d 48 (12)
45 (11)
0.4 —
—
—
—
—
Moura,
2009
TAC
Control
—
—
——
—
——
—
—
—
—
Sardella,
2009
Export Medtronic 38
37
3-5d 46.3 (8.6)
44.3 (9.5)
0.30 —
—
—
—
—
(EM)
Control
36
36
90d 49.0 (9.3)
46.7 (10.6)
0.3
Wita,
2009
Diver CE
Control
19
23
7d 50.1 (8.4)
46.5 (7.9)
19
23
39.5 (10.1)
32.3 (18.6)
0.14
Chao,
2008
Export Aspiration Catheter
Control
37
37
28d 56 (10)
57 (10)
0.51 37
37
49 (18)
†
53 (23)
†
0.54
Chevalier,
2008
Export Aspiration Catheter
Control
—
—
——
—
— 120
129
36.7 (18.0)
34.5 (21.5)
0.08
Ciszewski,
2008
Rescue/Diver
Control
32
31
5-8d 46.7 (11.0)
42.5 (10.0)
0.16 —
—
—
—
—
Ikari,
2008
TVAC
Control
103
113
180d 57.1 (12.5)
56.7 (12.3)
0.77 178
180
87.0 (32.4)
93.6 (78.6)
0.16
Svilaas,
2008
6F Export Aspiration Catheter
Control
—
—
——
—
— 535
536
28 (14-42)‡
26 (12-40)‡
0.92
DeLuca,
2006
Diver CE
Control
38
38
Post-PCI 37.29 (9.97)
36.67 (3.03)
> 0.05 —
—
—
—
—
35
36
180d 42.97 (9.97)
41.28 (3.37)
> 0.05
Kaltoft,
2006
Rescue Catheter
Control
108
107
30d 51 (43-57)†
53 (47-58)†
0.13 108
107
39 (29-48)‡
29 (23-38)‡
< 0.0001
Lee,
2006
Export Aspiration Catheter
Control
—
—
——
—
——
—
—
—
—
Silva-Orrego,
2006
Pronto Extraction Catheter
Control
—
—
——
—
— 74
74
57 (19)
54 (21)
0.36
Burzotta,
2005
Diver CE
Control
25
25
1d 50.36 (8.76)
45.75 (7.49)
< 0.05 50
49
81 (43)
72 (34)
0.41
25
25
7d 53.34 (10.99)
48.09 (9.4)
< 0.05
25
25
180d 53.28 (10.04)
47.72 (8.28)
< 0.05
Noel,
2005
Export
Control
—
—
——
—
——
—
—
—
—
Dudek,
2004
Rescue
Control
35
32
In-hospital 56.5 (9.1)
52.8 (12.8)
> 0.05 —
—
—
—
—
35
32
90d 60.3 (9.2)
55.3 (14.7)
> 0.05
Mechanical Thrombectomy
Migliorini,
2010
AngioJet Rheolytic Thrombectomy
Control
—
—
——
—
— 256
245
59.5 (44.7-70)‡
46 (35-60)‡
< 0.001
Ali,
2006
AngioJet Catheter
Control
197
205
14-28d 51.3 (11.53)
52.3 (10.89)
0.38 240
240
75.4 (30.9)
59.2 (26.8)
< 0.001
Lefèvre,
2005
X-Sizer Catheter
Control
—
—
——
—
— 100
101
54 (28)
45 (25)
0.009
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Antoniucci,
2004
AngioJet
Control
—
—
——
—
——
—
—
—
—
Napodano,
2003
X-Sizer Catheter
Control
46
46
In-hospital 51.0 (7.7)
48.7 (10.9)
0.29 —
—
—
—
—
46
46
30d 51.9 (7.9)
49.9 (8.9)
0.26
Distal Filter Embolic Protection Devices
Ito,
2010
Filtrap
Control
—
—
—— — —
—
—
—
—
Kelbæk,
2008
FilterWire-EZ or SpiderX
Control
—
—
——
—
——
—
—
—
—
Cura,
2007
SpideRX
Control
70
70
2-3d 47.4 (9.9)
45.3 (7.3)
0.29 70
70
52 (43-70) ‡
43.5 (30-54) ‡
< 0.001
Guetta,
2007
FilterWire EZ
Control
51
49
Post-PCI 47 (—)
44 (—)
0.56 —
—
—
—
—
Lefèvre,
2004
AngioGuardXP
Control
—
—
——
—
——
—
—
—
—
Distal Balloon Embolic Protection Devices
Duan,
2010
PercuSurge Guardwire Plus 46
50
90d 51.6 (3.6)
49.3 (5.3)
< 0.05 —
—
—
—
—
Control 46
50
180d 53.0 (3.7)
50.8 (5.2)
< 0.05
Pan,
2010
PercuSurge Guardwire
Control
—
—
—— — —
—
—
—
—
Tahk,
2008
PercuSurge GuardWire
Control
48
47
180d 58.1 (11.4)
54.6 (10.3)
0.24 —
—
—
—
—
Hahn,
2007
GuardWire
Control
19
20
3d 50 (9)
49 (13)
0.60 —
—
—
—
—
15
14
180d 48 (16)
50 (9)
0.74
Matsuo,
2007
GuardWire Distal Protection
Control
80
74
Post-PCI 46.1 (9.5)
55.4 (13.9)
0.99 80
74
75.8 (30)
53 (25)
< 0.01
80
74
180d 61.9 (—)
62.7 (—)
0.36
Muramatsu,
2007
GuardWire Plus System
Control
173
168
Post-PCI 54.0 (—)
53.8 (—)
0.90 173
168
29.7 (18.3)§
29.5 (18.2)§
0.91
133
123
30d 55.3 (—)
55.4 (—)
> 0.05
108
117
180d 57.1 (—)
57.1 (—)
> 0.05
Zhou,
2007
PercuSurge GuardWire
Control
—
—
——
—
——
—
—
—
—
Okamura,
2005
PercuSurge GuardWire
Control
—
—
D/c (mean 22 ± 4 d) 47 (9)
48 (8)
0.89 8
8
—
—
—
Stone,
2005
GuardWire Plus
Control
—
—
——
—
— 252
249
53 (42-69)‡
39 (29-51)‡
< 0.001
Proximal Balloon Embolic Protection Devices
Haeck,
2009
Proxis
Control
96
110
4-6m 50 (11)
50 (12)
0.46 141
143
45 (36-58)‡
31 (25-40)‡
< 0.01
*Strength of evidence ratings for ejection fraction and prolonged procedure time, respectively, are: Catheter aspiration device moderate: high; Mechanical
Thrombectomy devices: moderate, high; Distal filter embolic protection devices: low, insufficient; Distal balloon embolic protection devices: moderate, low;
proximal balloon embolic protection devices: insufficient, moderate; embolic protection devices combined: moderate, moderate
† Lab to TIMI-3
‡ Median (interquartile range)
§ operation time
— not reported
Abbreviations: d = days; d/c = discharge; EF = ejection fraction; n = number of participants included in the analysis of ejection fraction; PCI = percutaneous
coronary intervention, SD = standard deviation; TAC = Thrombectomy Aspiration Catheter; TVAC = Transvascular aspiration catheter
Sobieraj et al. BMC Cardiovascular Disorders 2011, 11:74
http://www.biomedcentral.com/1471-2261/11/74
Page 12 of 19Additional material
Additional file 1: Literature search strategy. This file contains the
literature search strategy used for this review.
Additional file 2: Table S1. Baseline study characteristics. This file
contains an additional table with included trial baseline characteristics.
Additional file 3: Impact of catheter aspiration devices versus
control on mortality using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of catheter aspiration devices versus control on mortality
using the maximal duration of followup in patients with ST-segment
elevation myocardial infarction. The squares represent individual point
estimates. The size of the square represents the weight given to each
study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 4: Impact of mechanical thrombectomy devices
versus control on mortality using the maximal duration of followup
in patients with ST-segment elevation myocardial infarction. Figure
of the Impact of mechanical thrombectomy devices versus control on
mortality using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 5: Impact of distal filter embolic protection devices
versus control on mortality using the maximal duration of followup
in patients with ST- segment elevation myocardial infarction. Figure
of the Impact of distal filter embolic protection devices versus control on
mortality using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 6: Impact of distal balloon embolic protection
devices versus control on mortality using the maximal duration of
followup versus control in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of distal balloon embolic
protection devices versus control on mortality using the maximal
duration of followup versus control in patients with ST-segment
elevation myocardial infarction. The squares represent individual point
estimates. The size of the square represents the weight given to each
study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 7: Impact of embolic protection devices combined
versus control on mortality using the maximal duration of followup
in patients with ST- segment elevation myocardial infarction. Figure
of the Impact of embolic protection devices combined versus control on
mortality using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 8: Impact of catheter aspiration devices versus
control on myocardial infarction using the maximal duration of
followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of catheter aspiration devices versus
control on myocardial infarction using the maximal duration of followup
in patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
Additional file 9: Impact of mechanical thrombectomy devices
versus control on myocardial infarction using the maximal duration
of followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of mechanical thrombectomy devices
versus control on myocardial infarction using the maximal duration of
followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 10: Impact of distal filter embolic protection devices
versus control on myocardial infarction using the maximal duration
of followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of distal filter embolic protection devices
versus control on myocardial infarction using the maximal duration of
followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 11: Impact of distal balloon embolic protection
devices versus control on myocardial infarction using the maximal
duration of followup in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of distal balloon embolic
protection devices versus control on myocardial infarction using the
maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 12: Impact of embolic protection devices combined
versus control on myocardial infarction using the maximal duration
of followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of embolic protection devices combined
versus control on myocardial infarction using the maximal duration of
followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 13: Impact of catheter aspiration devices versus
control on stroke using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of catheter aspiration devices versus control on stroke using
the maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 14: Impact of mechanical thrombectomy devices
versus control on occurrence of stroke using the maximal duration
of followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of mechanical thrombectomy devices
versus control on occurrence of stroke using the maximal duration of
followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
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Page 13 of 19intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 15: Impact of embolic protection devices combined
versus control on stroke using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of embolic protection devices combined versus control on
stroke using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 16: Impact of catheter aspiration devices versus
control on target revascularization using the maximal duration of
followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of catheter aspiration devices versus
control on target revascularization using the maximal duration of
followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 17: Impact of mechanical thrombectomy devices
versus control on target revascularization using the maximal
duration of followup in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of mechanical
thrombectomy devices versus control on target revascularization using
the maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 18: Impact of distal filter embolic protection devices
versus control on target revascularization using the maximal
duration of followup in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of distal filter embolic
protection devices versus control on target revascularization using the
maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 19: Impact of distal balloon embolic protection
devices versus control on target revascularization using maximal
duration of followup in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of distal balloon embolic
protection devices versus control on target revascularization using
maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 20: Impact of embolic protection devices combined
versus control on target revascularization using the maximal
duration of followup in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of embolic protection
devices combined versus control on target revascularization using the
maximal duration of followup in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 21: Impact of catheter aspiration devices versus
control on MACE of maximal duration of followup in patients with
ST-segment elevation myocardial infarction. Figure of the Impact of
catheter aspiration devices versus control on MACE of maximal duration
of followup in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 22: Impact of mechanical thrombectomy devices
versus control on MACE using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of mechanical thrombectomy devices versus control on
MACE using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 23: Impact of distal filter embolic protection devices
versus control on MACE using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of distal filter embolic protection devices versus control on
MACE using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 24: Impact of distal balloon embolic protection
devices versus control on MACE using the maximal duration of
followup in patients with ST-segment elevation myocardial
infarction. Figure of the Impact of distal balloon embolic protection
devices versus control on MACE using the maximal duration of followup
in patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
Additional file 25: Impact of embolic protection devices combined
versus control on MACE using the maximal duration of followup in
patients with ST-segment elevation myocardial infarction. Figure of
the Impact of embolic protection devices combined versus control on
MACE using the maximal duration of followup in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 26: Impact of catheter aspiration devices versus
control on ST-segment resolution in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of catheter
aspiration devices versus control on ST-segment resolution in patients
with ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 27: Impact of mechanical thrombectomy devices
versus control on ST-segment resolution in patients with ST-
segment elevation myocardial infarction Figure of the Impact of
mechanical thrombectomy devices versus control on ST-segment
resolution in patients with ST-segment elevation myocardial
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the square represents the weight given to each study in the meta-
analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 28: Impact of distal filter embolic protection devices
versus control on ST-segment resolution in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
distal filter embolic protection devices versus control on ST-segment
resolution in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 29: Impact of distal balloon embolic protection
devices versus control on ST-segment resolution in patients with
ST-segment elevation myocardial infarction. Figure of the Impact of
distal balloon embolic protection devices versus control on ST-segment
resolution in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 30: Impact of embolic protection devices combined
versus control on ST-segment resolution in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
embolic protection devices combined versus control on ST-segment
resolution in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 31: Impact of catheter aspiration devices versus
control on myocardial blush grade of 3 in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of catheter
aspiration devices versus control on myocardial blush grade of 3 in
patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
Additional file 32: Impact of mechanical thrombectomy devices
versus control on myocardial blush grade of 3 in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
mechanical thrombectomy devices versus control on myocardial blush
grade of 3 in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 33: Impact of distal filter embolic protection devices
versus control on myocardial blush grade of 3 in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
distal filter embolic protection devices versus control on myocardial
blush grade of 3 in patients with ST-segment elevation myocardial
infarction. The squares represent individual point estimates. The size of
the square represents the weight given to each study in the meta-
analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 34: Impact of distal balloon embolic protection
devices versus control on myocardial blush grade of 3 in patients
with ST-segment elevation myocardial infarction. Figure of the
Impact of distal balloon embolic protection devices versus control on
myocardial blush grade of 3 in patients with ST-segment elevation
myocardial infarction. The squares represent individual point estimates.
The size of the square represents the weight given to each study in the
meta-analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 35: Impact of embolic protection devices combined
versus control on myocardial blush grade of 3 in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
embolic protection devices combined versus control on myocardial
blush grade of 3 in patients with ST-segment elevation myocardial
infarction. The squares represent individual point estimates. The size of
the square represents the weight given to each study in the meta-
analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 36: Impact of catheter aspiration devices versus
control on TIMI-3 blood flow in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of catheter aspiration
devices versus control on TIMI-3 blood flow in patients with ST-segment
elevation myocardial infarction. The squares represent individual point
estimates. The size of the square represents the weight given to each
study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 37: Impact of mechanical thrombectomy devices
versus control on TIMI- 3 blood flow in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of mechanical
thrombectomy devices versus control on TIMI- 3 blood flow in patients
with ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 38: Impact of distal filter embolic protection devices
versus control on TIMI-3 blood flow in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of distal filter
embolic protection devices versus control on TIMI-3 blood flow in
patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
Additional file 39: Impact of distal balloon embolic protection
devices versus control on TIMI- 3 blood flow in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
distal balloon embolic protection devices versus control on TIMI- 3 blood
flow in patients with ST-segment elevation myocardial infarction. The
squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 40: Impact of embolic protection devices combined
versus control on TIMI-3 blood flow in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of embolic
protection devices combined versus control on TIMI-3 blood flow in
patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
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Page 15 of 19Additional file 41: Impact of catheter aspiration devices versus
control on distal embolization in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of catheter
aspiration devices versus control on distal embolization in patients with
ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 42: Impact of mechanical thrombectomy devices
versus control on distal embolization in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of mechanical
thrombectomy devices versus control on distal embolization in patients
with ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 43: Impact of distal balloon embolic protection
devices versus control on distal embolization in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
distal balloon embolic protection devices versus control on distal
embolization in patients with ST-segment elevation myocardial infarction.
The squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 44: Impact of embolic protection devices combined
versus control on distal embolization in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of embolic
protection devices combined versus control on distal embolization in
patients with ST-segment elevation myocardial infarction. The squares
represent individual point estimates. The size of the square represents
the weight given to each study in the meta-analysis. Horizontal lines
through each square represent 95 percent confidence intervals. The
diamond represents the combined results. The solid vertical line
extending from 1 is the null value.
Additional file 45: Impact of catheter aspiration devices versus
control on no reflow in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of catheter aspiration
devices versus control on no reflow in patients with ST-segment
elevation myocardial infarction. The squares represent individual point
estimates. The size of the square represents the weight given to each
study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 46: Impact of mechanical thrombectomy devices
versus control on no reflow in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of mechanical
thrombectomy devices versus control on no reflow in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 47: Impact of distal filter embolic protection devices
versus control on no reflow in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of distal filter embolic
protection devices versus control on no reflow in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 48: Impact of distal balloon embolic protection
devices versus control on no reflow in patients with ST-segment
elevation myocardial infarction Figure of the Impact of distal
balloon embolic protection devices versus control on no reflow in
patients with ST-segment elevation myocardial infarction. The
squares represent individual point estimates. The size of the square
represents the weight given to each study in the meta-analysis.
Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
Additional file 49: Impact of embolic protection devices combined
versus control on no reflow in patients with ST-segment elevation
myocardial infarction. Figure of the Impact of embolic protection
devices combined versus control on no reflow in patients with ST-
segment elevation myocardial infarction. The squares represent individual
point estimates. The size of the square represents the weight given to
each study in the meta-analysis. Horizontal lines through each square
represent 95 percent confidence intervals. The diamond represents the
combined results. The solid vertical line extending from 1 is the null
value.
Additional file 50: Impact of catheter aspiration devices on
coronary dissection versus control in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of catheter
aspiration devices on coronary dissection versus control in patients with
ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 51: Impact of mechanical thrombectomy devices on
coronary perforation versus control in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of mechanical
thrombectomy devices on coronary perforation versus control in patients
with ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 52: Impact of catheter aspiration devices on side
branch occlusion versus control in patients with ST-segment
elevation myocardial infarction. Figure of the Impact of catheter
aspiration devices on side branch occlusion versus control in patients
with ST-segment elevation myocardial infarction. The squares represent
individual point estimates. The size of the square represents the weight
given to each study in the meta-analysis. Horizontal lines through each
square represent 95 percent confidence intervals. The diamond
represents the combined results. The solid vertical line extending from 1
is the null value.
Additional file 53: Impact of distal balloon embolic protection
devices on side branch occlusion versus control in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
distal balloon embolic protection devices on side branch occlusion
versus control in patients with ST-segment elevation myocardial
infarction. The squares represent individual point estimates. The size of
the square represents the weight given to each study in the meta-
analysis. Horizontal lines through each square represent 95 percent
confidence intervals. The diamond represents the combined results. The
solid vertical line extending from 1 is the null value.
Additional file 54: Impact of embolic protection devices combined
on side branch occlusion versus control in patients with ST-
segment elevation myocardial infarction. Figure of the Impact of
embolic protection devices combined on side branch occlusion versus
control in patients with ST-segment elevation myocardial infarction. The
squares represent individual point estimates. The size of the square
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Horizontal lines through each square represent 95 percent confidence
intervals. The diamond represents the combined results. The solid vertical
line extending from 1 is the null value.
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